LakeShore Biopharma Co (LakeShore Biopharma Co) Debt-to-Equity : 1.00 (As of Sep. 2023)

View and export this data going back to 2023. Start your Free Trial

What is LakeShore Biopharma Co Debt-to-Equity?

LakeShore Biopharma Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $25.73 Mil. LakeShore Biopharma Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $50.21 Mil. LakeShore Biopharma Co's Total Stockholders Equity for the quarter that ended in Sep. 2023 was $76.34 Mil. LakeShore Biopharma Co's debt to equity for the quarter that ended in Sep. 2023 was 0.99.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for LakeShore Biopharma Co's Debt-to-Equity or its related term are showing as below:

LSB' s Debt-to-Equity Range Over the Past 10 Years
Min: -0.54 Med: -0.04 Max: 1
Current: 1

During the past 3 years, the highest Debt-to-Equity Ratio of LakeShore Biopharma Co was 1.00. The lowest was -0.54. And the median was -0.04.

LSB's Debt-to-Equity is ranked worse than
86.89% of 1068 companies
in the Biotechnology industry
Industry Median: 0.15 vs LSB: 1.00

LakeShore Biopharma Co Debt-to-Equity Historical Data

The historical data trend for LakeShore Biopharma Co's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

LakeShore Biopharma Co Debt-to-Equity Chart

LakeShore Biopharma Co Annual Data

Trend

Mar21

Mar22

Mar23

Debt-to-Equity

-0.04

-0.54

0.69

LakeShore Biopharma Co Semi-Annual Data
	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23
Debt-to-Equity	Get a 7-Day Free Trial			N/A	-0.54	-0.49	0.69	1.00

Competitive Comparison of LakeShore Biopharma Co's Debt-to-Equity

For the Biotechnology subindustry, LakeShore Biopharma Co's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

LakeShore Biopharma Co's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, LakeShore Biopharma Co's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where LakeShore Biopharma Co's Debt-to-Equity falls into.

LakeShore Biopharma Co Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

LakeShore Biopharma Co's Debt to Equity Ratio for the fiscal year that ended in Mar. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(28.805	+	43.556)	/	105.712
	=	0.68

LakeShore Biopharma Co's Debt to Equity Ratio for the quarter that ended in Sep. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(25.729	+	50.21)	/	76.336
	=	0.99

LakeShore Biopharma Co (NAS:LSB) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

LakeShore Biopharma Co Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of LakeShore Biopharma Co's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

LakeShore Biopharma Co (LakeShore Biopharma Co) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » LakeShore Biopharma Co Ltd (NAS:LSB) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

H6Z:Germany

Address

38 Yongda Road, Building No. 2, Daxing Biomedical Industry Park, Daxing District, Beijing, CHN, 102629

Website

https://www.yishengbio.com

YS Biopharma Co Ltd is principally engaged in the research, development, manufacturing and sale of vaccines and therapeutic biologics. It developed a PIKA immunomodulating technology platform and a series of product candidates targeting rabies, hepatitis B, influenza and other indications. It is also conducting the production and sale of YSJA, a rabies vaccine, the first aluminium-free lyophilized rabies vaccine that was launched in China. It has one operating segment, which is the development, production, marketing and sale of biopharmaceutical products.